For Subscribers

Get the complete article now!

TWST: Is there any one specific area that you feel will grow the most?

Mr. Murphy: There are many potential applications of our technology many of which require clinical evaluation and others remain as concepts at this stage. The intranasal delivery of insulin is an example of a product that could compete in a very large worldwide market. To date the primary method of administration is by injection. Diabetic patients, especially children, are looking for a more convenient and less invasive forms of administration. Pain management, as it pertains to muscle aches or migraines, is another area where more convenient forms of delivery could compete in a very large market.

TWST: What other large trends are coming before you in the next few years, and how does your company fit in?

Mr. Murphy: I believe the drug delivery industry as a whole will become a more important asset to the pharmaceutical industry. Improved delivery provides significant value in convenience, efficacy, drug utilization and patent life extension.

TWST: What are the milestones that you would like to pass over the next few years?

Mr. Murphy: We intend to continue to build upon the base business we have in Europe, and then, to expand into other European nations. We are currently exporting to other Spanish-speaking nations in Central and South America, also exporting into Northern Africa, and the Middle East. We hope to enter into several licensing agreements with multinational companies to market products based upon our proprietary drug delivery technology.

TWST: What are your strengths as a company?

Mr. Murphy: We have a strong and experienced management team in the US and Europe. Many of the senior executives and Directors of the company have years of past experience at SmithKline Beecham. The Directors of the company are proactive and contribute their expertise to assist management.

TWST: If you were standing on a plateau two or three years from now looking back, what would you like to see?

Mr. Murphy: I would like to look back upon a number of licenses that laid the foundation for the launch of new proprietary products in a variety of therapeutic classes. I would also like to reflect upon our contribution to therapies that are noninvasive for the patients.

TWST: What are some of the best reasons why long term investors should consider Bentley Pharmaceutical (AMEX:BNT)?

Mr. Murphy: When considering other drug delivery companies such as ALZA Corporation, Elan Corporation, and Watson Pharmaceuticals, each grew significantly in drug delivery,building upon their base technologies. Although they continue to license technology, eventually each found it desirable to accumulate a portfolio of products to market. Bentley took a reverse route by building a portfolio of product and then emerging into the drug delivery field with the acquisition of technology. Our portfolio of product is growing at a tremendous rate and will accelerate due to the future contributions from the alliance with Teva Pharmaceuticals. Meanwhile, our drug delivery technology provides us with a supply of new proprietary opportunities and ability to emerge within this group of leading drug delivery companies.